Last reviewed · How we verify
NCT06843889
A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
Phase 2 trial testing Toripalimab (240mg day1, Q3W*3cycle) in Locally Advanced Esophageal Squamous Cell Carcinoma in 34 participants. Currently enrolling.
1 August 2027
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 3 April 2025 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 August 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Toripalimab (240mg day1, Q3W*3cycle) — full drug profile →
Conditions studied
- Locally Advanced Esophageal Squamous Cell Carcinoma — all drugs for Locally Advanced Esophageal Squamous Cell Carcinoma →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 18 to 75, any sex, with Locally Advanced Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a single-center, open phase II clinical study. 34 patients with resectable local middle and advanced esophageal squamous cell carcinoma were treated with anti-PD-1 antibody combined with sequential chemoratherapy regimen: Phase I:Toripalimab (240mg day1, Q3W\*2cycle) + clinical routine chemotherapy regimen selected by the investigator; The second stage: Toripalimab (240mg day1, Q3W\*1cycle) + radiotherapy (intensity modulated radiotherapy, 40Gy/20F, 2Gy/F); Surgery was performed 4-6 weeks after completion, and subsequent treatment options were considered after surgery according to MDT discussion. According to the postoperative pathological results, the pathological complete response (pCR) and major response (MPR) were evaluated. The disease-free survival (DFS), overall survival (OS), 1 or 2 years survival rate and adverse reactions were recorded.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Divergent immuno-landscapes: comparing the tumor microenvironment of Indian and Western HNSCC patients.
Kumar Rai P, Choudhary B. · · 2026 · PMID 42111272 · DOI 10.3389/fcell.2026.1725978 -
The safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review.
Shen Q, Liu H, Xue H, Yilixiati A, et al · · 2026 · PMID 41743735 · DOI 10.3389/fimmu.2026.1687326
Verify or expand the search:
- PubMed search for NCT06843889
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Toripalimab (240mg day1, Q3W*3cycle)
Trials testing the same drug.
- NCT07358689 — Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatm · Phase 2 · not yet recruiting
Other recruiting trials for Locally Advanced Esophageal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT06356688 — A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as · Phase 2 · recruiting
- NCT06342167 — Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carc · Phase 2 · active not recruiting
- NCT06187597 — Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) · Phase 2 · recruiting
- NCT06907602 — Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma · Phase 2, PHASE3 · recruiting
- NCT05520619 — Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) · Phase 2 · active not recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06843889 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06843889.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing